Denosumab (Prolia) for Postmenopausal Osteoporosis

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2010年 / 52卷 / 1349期
关键词：
BONE TURNOVER; WOMEN; ALENDRONATE;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [1] Denosumab (Prolia) for Treatment of Postmenopausal Osteoporosis
    Johnson, Gretchen L.
    AMERICAN FAMILY PHYSICIAN, 2012, 85 (04) : 334 - +
  • [2] EMA approves Prolia® (denosumab) for the treatment of postmenopausal osteoporosis
    不详
    IMMUNOTHERAPY, 2010, 2 (04) : 438 - 438
  • [3] Denosumab (Prolia): Analysis of an Outpatient Osteoporosis Management Service
    Beathard, W. A.
    Grimes, A.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 70 : S236 - S236
  • [4] PHARMACOKINETICS AND PHARMACODYNAMICS OF CT-P41, A PROPOSED DENOSUMAB BIOSIMILAR, COMPARED TO REFERENCE DENOSUMAB (PROLIA) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Reginster, J. -Y.
    Czerwinski, E.
    Strzelecka, A.
    Szymanowski, K.
    Postol, S.
    Poder, A.
    Supronik, J.
    Wilk, K.
    Borowy, P.
    Budlewski, T.
    Janowska-Maus, M.
    Kwiatek, J.
    Kim, S. H.
    Suh, J. H.
    Han, N. R.
    Kim, N. H.
    Bae, S. H.
    Silverman, S. L.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S341 - S342
  • [5] EFFICACY AND SAFETY OF CT-P41, A PROPOSED DENOSUMAB BIOSIMILAR, COMPARED TO REFERENCE DENOSUMAB (PROLIA) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Reginster, J. -Y.
    Czerwinski, E.
    Strzelecka, A.
    Szymanowski, K.
    Postol, S.
    Poder, A.
    Supronik, J.
    Wilk, K.
    Borowy, P.
    Budlewski, T.
    Janowska-Maus, M.
    Kwiatek, J.
    Kim, S. H.
    Suh, J. H.
    Han, N. R.
    Kim, N. H.
    Bae, S. H.
    Silverman, S. L.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S341 - S341
  • [6] EFFICACY AND SAFETY OF CT-P41, A PROPOSED DENOSUMAB BIOSIMILAR, COMPARED TO REFERENCE DENOSUMAB (PROLIA) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Reginster, J. -Y.
    Czerwinski, E.
    Strzelecka, A.
    Szymanowski, K.
    Postol, S.
    Poder, A.
    Supronik, J.
    Wilk, K.
    Borowy, P.
    Budlewski, T.
    Janowska-Maus, M.
    Kwiatek, J.
    Kim, S. H.
    Suh, J. H.
    Han, N. R.
    Kim, N. H.
    Bae, S. H.
    Silverman, S. L.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S27 - S27
  • [7] Denosumab (Prolia): Analysis of an Outpatient Osteoporosis Management Service
    不详
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 : S236 - S236
  • [8] Persistence At 12 Months With Denosumab (Prolia®) In Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study
    Silverman, Stuart L.
    Siris, Ethel
    Kendler, David L.
    Belazi, Dea
    Brown, Jacques P.
    Gold, Deborah T.
    Lewiecki, E. Michael
    Papaioannou, Alexandra
    Simonelli, Christine
    Ferreira, Irene
    Dakin, Paula
    Siddhanti, Suresh
    Stolshek, Bradley
    Recknor, Christopher
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S523 - S523
  • [9] Spotlight on Denosumab in Postmenopausal Osteoporosis
    Moen, Marit D.
    Keam, Susan J.
    BIODRUGS, 2011, 25 (04) : 261 - 264
  • [10] Denosumab for the Management of Postmenopausal Osteoporosis
    Singer, Andrea
    Grauer, Andreas
    POSTGRADUATE MEDICINE, 2010, 122 (06) : 176 - 187
12345